Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fiserv Inc. Common Stock (FISV) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Fiserv Inc. Common StockTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Fiserv Inc. Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Fiserv Inc. Common Stock trades at $46.17 (market cap $24.81B), while Inovio Pharmaceuticals Inc trades at $0.96 (market cap $103.19M). The key difference: Fiserv Inc. Common Stock is far larger — about 240.4× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Fiserv Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiserv Inc. Common Stock for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.

FISVINO
Market Cap
$24.81B$103.19M
Volume
4,091,2348,461,580
Sector
TechnologyHealth
52-Week High
$126.54$2.60
52-Week Low
$44.36$0.66
Typical Hold Time
0 Days43 Days
Enterprise Value
$52.60B$74.52M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fiserv Inc. Common Stock

No Aura AI signal available yet.

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.

The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FISV
100% Buy0% Sell
Avg holding period · 0 Days
INO
97% Buy3% Sell
Avg holding period · 43 Days

Top news

Latest headlines on both assets

About Fiserv Inc. Common Stock

Fiserv, Inc. is a global provider of payments and financial services technology, offering merchant acquiring, digital commerce, and financial solutions through its Merchant Solutions and Financial Solutions segments.

Read more on FISV →

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →